Medical Xpress

NOVEMBER 29, 2022

Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10-year risk of death from a heart attack or stroke stemming from atherosclerotic cardiovascular disease. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

Radiology 98

Radiology Development Research Cardiology 98

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Radiology 52

Radiology Cardiology Development Production 52

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Billion Myovant/ Pfizer Deal. Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.

Trials 52

Trials Drugs Hormones Radiology 52

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

OCTOBER 14, 2020

Felker and Dr. Udelson join current advisors to support the development ofalfapump ® DSR for the management of fluid overload in patients with heart failure. The Sequana Medical management team is working closely with its advisors on the development of alfa pump DSR (Direct Sodium Removal). GHENT, Belgium, Oct.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40